Sol-Gel Technologies (SLGL) Enterprise Value (2016 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly Enterprise Value of -$10.1 million for Q1 2026, up 39.99% year-over-year from -$7.2 million in Q1 2025, and up 57.76% quarter-over-quarter from -$24.0 million in Q4 2025.
Sol-Gel Technologies (SLGL) Enterprise Value (2016 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Enterprise Value for 11 consecutive years, with -$10.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value rose 39.99% year-over-year to -$10.1 million; the TTM figure through Mar 2026 stood at -$10.1 million (up 39.99% YoY), while the FY2025 annual figure was -$24.0 million, up 4.35% from the prior year.
- Enterprise Value improved to -$10.1 million in Q1 2026 per SLGL's latest filing, from -$24.0 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$6.7 million in Q3 2025 and bottomed at -$42.2 million in Q2 2022.
- Historically, Enterprise Value has averaged -$20.3 million across 5 years, with a median of -$21.1 million in 2022.
- On a YoY basis, Enterprise Value climbed as much as 80.39% in 2022 and fell as far as 68.07% in 2022.
- Sol-Gel Technologies' Enterprise Value stood at -$21.1 million in 2022, then slumped by 32.46% to -$28.0 million in 2023, then grew by 14.54% to -$23.9 million in 2024, then retreated by 0.36% to -$24.0 million in 2025, then surged by 57.76% to -$10.1 million in 2026.
- Business Quant data shows SLGL's Enterprise Value at -$10.1 million in Q1 2026, -$24.0 million in Q4 2025, and -$6.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Sol-Gel Technologies | 240.26 Mn | 230.12 Mn | - | -10.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.14 Mn |
| Dec 31, 2025 | -24.00 Mn |
| Sep 30, 2025 | -6.71 Mn |
| Jun 30, 2025 | -34.72 Mn |
| Mar 31, 2025 | -16.89 Mn |
| Dec 31, 2024 | -23.91 Mn |
| Sep 30, 2024 | -13.42 Mn |
| Jun 30, 2024 | -27.62 Mn |
| Mar 31, 2024 | -11.21 Mn |
| Dec 31, 2023 | -27.98 Mn |
| Sep 30, 2023 | -14.14 Mn |
| Jun 30, 2023 | -34.65 Mn |
| Mar 31, 2023 | -6.81 Mn |
| Dec 31, 2022 | -21.13 Mn |
| Sep 30, 2022 | -8.50 Mn |
| Jun 30, 2022 | -42.24 Mn |
| Mar 31, 2022 | -21.25 Mn |
| Dec 31, 2021 | -21.79 Mn |
| Sep 30, 2021 | -43.35 Mn |
| Jun 30, 2021 | -33.20 Mn |